Erythromycin A released peptidyl-tRNA in the in vitro polypeptide synthesis system with bacterial components programmed by synthetic polynucleotide. This is consistent with our hypothesis that erythromycin A inhibits translocation by preventing proper situation of oligopeptidyltRNA in the donor (D) site on ribosomes.
Erythromycin A has been shown to inhibit the translocation step (1-3) as well as the peptidyl transferase step (4) of polypeptide formation. In an attempt to correlate these observations, a unitary hypothesis was proposed in which erythromycin inhibits translocation by preventing polypeptidyltRNA from situating itself properly at the donor (D or P) site while it would still allow the movement of the polypeptidyltRNA to the vicinity of the D-site (1) .
One logical extension of the above hypothesis is that peptidyl-tRNA which was hindered by erythromycin from situating itself correctly at the D site might well be unstable and would, therefore, be released from ribosomes. This communication presents evidence that this is indeed the case. Erythromycin A releases oligopeptidyl-tRNA from ribosomes in an in vitro protein synthesizing system. This finding correlates with the accumulation of oligopeptide in the presence of erythromycin A (5, 6) , as well as instability of ribosomal complexes blocked by erythromycin (20) .
MATERIALS AND METHODS
Escherichia coli Extract and Other Materials. E. coli Q13 (middle of the logarithmic phase of growth) was purchased from General Biochemicals Co. Preparations of soluble enzymes, S-150 (8), and ribosomes (9) were described previously. Soluble enzymes free of peptidyl-tRNA hydrolase were prepared as described elsewheret. The sources of the antibiotics were described previously (1, 8, 10, 11) . Details of each experiment can be found in the legends.
RESULTS
Releasing action of erythromycin A on peptidyl-tRNA in an in vitro protein synthesizing system with synthetic polynucleotide
In the experiment shown in Table 1 
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A, the ratio of released polyphenylalanine to that bound to ribosomes increased at least 4-fold, indicating that release of polyphenylalanine takes place in the presence of this antibiotic. In confirmation of previous results (1), erythromycin had only a slight effect on the overall polyphenylalanine synthesis.
Since it is known that oligolysine accumulates in the presence of erythromycin A (5), the possibility that oligolysyltRNA is released from ribosomes in the presence of erythromycin A was also examined. In the experiment shown in Table 2 , erythromycin A was added to a polylysine synthesis system and the released materials were analyzed by paper chromatography to separate oligolysine from mono-and polylysine (12) . It is clear from this table that the amounts of released dilysyl-and trilysyl-tRNA were markedly increased in the presence of erythromycin A, while in the presence of micrococcin, which is known to fix aminoacyl-tRNA to ribosomes (11) , no appreciable release of oligolysyl-tRNA was observed.
In order to establish the nature of the material which is released from ribosomes, the radioactive material in the soluble fraction was subjected to sucrose gradient centrifugation. As shown in Fig. 1 , the peak of the radioactivity was found at the position where [14C]lysyl-tRNA was sedimented, indicating that the radioactivity released from ribosomes was still bound to tRNA. To further establish the fact that the radioactive material is bound to tRNA, the peak fractions were treated with alkali or RNase A. Almost all radioactivity became acid soluble (data not shown). The analysis of the radioactivity released by the alkaline treatment indicated that 31.4% and 32.2% were tri-and dilysine, respectively.
It has been reported that in the presence of erythromycin A oligolysine rather than oligolysyl-tRNA accumulates (5) . In the present polylysine-forming system, we have used a soluble fraction free of peptidyl-tRNA hydrolase (13) (14) (15) (16) (17) , thereby avoiding the complication of formation of oligolysine. As shown in Fig. 2 , the material released by erythromycin in the polylysine synthesis system is susceptible to this enzyme, which was in the crude soluble fraction, supporting further the notion that released oligolysine is covalently linked to tRNA. The data in this figure also show that our partially purified soluble fraction is free of peptidyl-tRNA hydrolase and peptidyl-tRNA remains intact.
The release of formyl-('4C]methionyl-peptidyl-tRNA from ribosomes If the notion that erythromycin A releases oligopeptidyltRNA is correct, one would expect formyl-['4C]methionylpeptidyl-tRNA to be released in the presence of erythromycin A in the natural polypeptide synthesis system. In the experiment shown in Table 3 , a complex of ribosome, formyl- The oligolysine thus released from tRNA was analyzed by the paper chromotography method (13) .
* This represents the amounts obtained from the alkaline-sensitive radioactivity. FIG. 1. The sedimentation behavior of the materials released by erythromycin A. The reaction mixture for polylysine synthesis and the preparation of the released oligolysine were described in Table 2 . The alcohol-precipitable materials were isolated by adding two volumes of ethanol and the precipitate was dissolved in water. After removing the residual ethanol with ether, the solution (0.19 ml) was placed on 4.8 ml of a sucrose gradient [5-20% in 10 mM Tris.HCl (pH 7.2), 10 mM NH4Cl, and 13 mM Mg acetate] and the tubes were centrifuged for 17 hr at 45,000 rpm with a SW 50.1 rotor. The drops were collected from the bottom of the tube and the radioactivity (in 10 Mul) insoluble in cold trichloroacetic acid was measured by the filter disc method. Peaks of the radioactivity (fractions 7-12) were pooled and were used in the experiment described in Fig. 2 consistent with the notion that erythromycin A releases peptidyl-tRNA from ribosomes.
DISCUSSION
The mode of action of erythromycin A has been a somewhat controversial matter. It was originally proposed that erythromycin A may be a specific inhibitor of translocation in vivo (3) as well as in vitro (2) . On the basis of the observation that the release of tRNA accompanying the translocation process was strongly inhibited by erythromycin A, it was concluded that the translocation step was inhibited in vitro. Supporting evidence that erythromycin A may inhibit in a similar fashion in vivo has been obtained from the observation that in vivo treatment with erythromycin A resulted in the accumulation of peptidyl-tRNA at the acceptor (A) site (3) . On the other hand, erythromycin A has been shown to be an effective inhibitor of peptide bond formation depending on the type of peptidyl-tRNA. Thus, in the case of diphenylalanyltRNA, N-acetyldiphenylalanyl-tRNA, prolyl-glycyl-tRNA, phenylalanyl-leucyl-tRNA, and phenylalanyl-glycyl-tRNA the puromycin reaction with these oligopeptidyl-tRNAs is clearly inhibited (4) . Since the inhibition of peptidyl-puromycin formation occurred under conditions not requiring an enzymatic translocation step (18) , this suggested that erythromycin is a peptidyl transferase inhibitor. In an attempt to unify these contradictory observations, a hypothesis was proposed which suggested that erythromycin A allows translocation of peptidyl-tRNA to a point very close to the D site, but not to the extent that this peptidyl-tRNA will push out the unesterified tRNA which is occupying the D site (donor site, or often called P site). This hypothesis was supported by the observation that (a) evacuation of the A site during the translocation reaction was not inhibited by erythromycin A, (b) depending on the type of peptidyltRNA, the inhibitory effect of erythromycin on the peptide bond formation with puromycin varied, indicating that erythromycin A is not a universal inhibitor of peptide bond formation, and (c) the release of tRNA which accompanies translocation was inhibited by erythromycin A (1). This hypothesis, however, did not explain the observation that while polylysine formation was markedly inhibited in the presence of erythromycin A, oligolysine accumulates. To accommodate this observation, we extended our previous hypothesis by postulating that the peptidyl-tRNA which was moved into the vicinity of the D site but not to the D site itself is unstable, so that it will often be released from ribosomes. As presented in this communication, in (19) that erythromycin increased the amount of peptidyl-tRNA in vivo in a mutant with a temperature-sensitive hydrolase correlates very well with the present hypothesis. The efficiency of inhibition and release by erythromycin is dependent on the nature of peptide group. Thus, erythromycin inhibits polylysine synthesis more than polyphenylalanine synthesis (1) . The observation that oligopeptidyl-tRNA is released from ribosomes is consistent with the recent report (20) that erythromycin blocks the ribosomes shortly after initiation and the blocked complexes are unstable. It appears that erythromycin cannot exert its action on the ribosomes with long polypeptidyl-tRNA because of its inability to bind to such ribosomes (20) (21) (22) (23) , while single free ribosomes or initiating ribosomes are susceptible. The unstable nature of the ribosomepeptidyl-tRNA complex with erythromycin is reminiscent of the similar action of streptomycin (7), which has an inhibitory action on translocation (2) .
